Hemanext Expands Board of Directors with Two New Members
Joe Grogan is a healthcare expert with over two decades of experience in both the private sector and government, particularly in Washington, DC. He began his career as Executive Director of the Presidential Advisory Council on HIV and AIDS during the George W. Bush administration and later worked at the Food and Drug Administration (FDA). In the private sector, he advised Wall Street investors and worked for Amgen and Gilead Sciences, where he founded Gilead's DC office and led federal efforts during three major drug launches. Joe also served at the Office of Management and Budget, managing over $1.3 trillion in healthcare spending and drafting health sections of three Presidential Budgets. He later served as Domestic Policy Advisor in the West Wing, leading healthcare policy development and contributing to the President's Covid Task Force. Joe founded Fire Arrow to guide innovators through the complexities of Washington, DC, and help deliver products to those in need.
Phil M Pead is a seasoned technology executive and board member with over 40 years of leadership experience in the Healthcare IT and software industries. He has served as CEO of Per-Se Technologies, Eclipsys, and Progress Software, leading major turnarounds, mergers, and acquisitions. He currently sits on the boards of Modernizing Medicine and WebPT and has held past roles with Change Healthcare and Allscripts. A Harvard Business Review case study highlights his leadership at Per-Se, and he has taught the 'Managing in Adversity' class at MIT Sloan Business School for four years. He is also a national board member and Secretary for the Posse Foundation.
Andrew Dunham, CEO of Hemanext, warmly welcomes the addition to Hemanext's Board of Directors, 'We're thrilled to welcome Joe and Phil to our Board of Directors. Their expertise and vision will be invaluable as we continue to grow and innovate. We're excited for the journey ahead with such strong additions to our leadership team.'
About Hemanext
Hemanext is a privately held medical technology company based in Lexington, MA, that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts focus on the study of hypoxically stored Red Blood Cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs worldwide.
Visit Hemanext.com to learn more about the Company.
About Hemanext ONE
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. It is intended to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced (LR RBC) that have been prepared within the standard 8-hour hold time. Processing of Red Blood Cells processed with the Hemanext ONE system must be initiated within 8 hours of collection and completed within 12 hours of collection. The Red Blood Cells must be processed at room temperature (20-26°C). The Hemanext ONE system limits O2 and CO2 levels in the storage environment. Red Blood Cells Leukocytes Reduced, O2/ CO2 Reduced may be stored for up to 42 days at 1-6°C. Hemanext ONE is used for volumes no greater than 350 mL of LR RBC.
In Europe, Hemanext ONE is CE marked, which allows its commercial distribution within the market of the European Economic Area (EEA).
The Hemanext ONE RBC Processing and Storage system limits oxygen, the fuel for oxidative damage, providing a higher quality blood product (1,2,3). It has the potential to benefit all patients requiring transfusion for chronic conditions, such as thalassemia (4), sickle cell disease (SCD) (5), and myelodysplastic syndromes (MDS) (6), as well as those in need of critical transfusions during acute bleeding in surgery, trauma and other medical procedures (7).
Hemanext ONE creates hypoxic RBCs, RBCs that have been processed to reduce oxygen and carbon dioxide content of RBCs and to maintain these levels throughout storage up to 42 days (3). Hypoxic RBCs have demonstrated positive impacts on multiple in vitro metrics of RBC quality in preclinical studies (8,9). Clinical studies are underway to determine the impact of hypoxic RBCs on patient outcomes and estimate potential cost savings from expected improvements in care and reductions in transfusion volumes (10).
Hemanext Media Contact
Robert Haime
Vice President, Commercial
[email protected]
(781) 301-7474
References
1. Rabcuka J, Blonski S, Meli A, et al. Metabolic reprogramming under hypoxic storage preserves faster oxygen unloading from stored red blood cells. Blood Adv. 2022;6(18):5415-5428. doi: 10.1182/bloodadvances.2022007774
2. Reisz JA, Wither MJ et al. Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. 2016;128(12): e32-42.
3. Hemanext ONE® (Blood container set used to process and store CP2D/AS-3 Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced) [US Instructions for Use]. Lexington, MA: Hemanext Inc.
4. Farmakis D, Porter J, Taher A, et al. 2021 Thalassemia International Federation Guidelines for the management of transfusion-dependent thalassemia. 2022;6:8.
5. Chou S, Alsawas M, Fasano R, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:2.
6. Germing U, Oliva E, Hiwase D, and Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. 2019;3(6). doi: 10.1097/HS9.0000000000000314
7. American College of Surgeons. ACS TQIP massive transfusion in trauma guidelines. ACS TQIP. 2014; https://www.facs.org/media/zcjdtrd1/transfusion_guildelines.pdf.
8. Yoshida T, Blair A, D'Alessandro A, et al. Enhancing uniformity and overall quality of red cell concentrate with anaerobic storage. Blood Transfus. 2017;15(2):172-81.
9. Yoshida T, McMahon E, Croxon H, et al. The oxygen saturation of red blood cell concentrates: The basis for a novel index of red cell oxidative stress. Transfusion. 2022;62(1):183-193. doi: 10.1111/trf.16715.
10. Reikvam H, Hetland G, Ezligini F, et al. Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis. Transfus Apher Sci. 2023; doi: 10.1016/j.transci.2023.103755.
Contact Information:
Hemanext
Robert Haime, Vice President, Commercial
(781) 301-7474
Contact via Email
https://hemanext.com
Read the full story here: Hemanext Expands Board of Directors with Two New Members
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
12 hours ago
- New York Post
Coveted Trader Joe's mini tote bags that resell for up to $50K are returning to stores this fall
Trader Joe's viral mini tote bags are up for grabs. The grocery store chain confirmed to USA Today that it plans to bring back its beloved bag for the fall season. While a spokesperson for Trader Joe's declined to give any more information regarding colors, price or when the totes hit stores again, the Reno Gazette-Journal reported last week that the bags will be available in black, orange, purple and multicolored. It was also reported that the bite-sized bags will stay priced at $2.99. It's expected that some store locations will limit how many bags each customer can purchase, as they did with the former mini tote bag drops. Trader Joe's advised customers to ask a Crew Member in their neighborhood store about availability. The last batch of mini totes was released in April for Spring in pastel shades of blue, pink, purple and green. In March 2024, the 13x11x6-inch carriers quickly became a sensation, prompting die-hard Joe-heads to wait in long lines just to get their hands on one. They were even being resold on eBay at astronomical prices due to the high demand. As of the time of reporting, the Spring-colored mini totes are listed on eBay for an eye-popping $50,000. That's a big increase in price compared to the most expensive listing on eBay the week they were released, which was a single tote bag in pastel pink for $1,699. The Reno Gazette-Journal reported last week that the bags will be available in black, orange, purple and multicolored. AP Photo/Christina Paciolla 'The adorable totes in question are made of the same heavy-duty, 65% cotton/35% polyester blend as our larger, classic Canvas Bags,' the product page for the Mini Canvas Tote Bag said — noting that the bags also have the same 'long, comfortable handles.' The only real difference, the company stated, is the diminutive size. While the mini canvas tote bags are not yet available, Trader Joe's is currently selling the mini insulated totes. The insulated bags are about the size of a lunch box and are available in two colors, blue and peach, for $3.99 each. In March 2024, the totes quickly became a sensation — with customers waiting in long lines just to get their hands on one. Mark Kauzlarich/Bloomberg via Getty Images Trader Joe's mini tote bags have even made their way across the pond — even without a single location in Britain, Trader Joe's bags have become a must-have accessory. One girl on TikTok said that since she moved to London, she's noticed that so many people carry Trader Joe's bags — and claimed that she's seen more there than she did in America. And while many people on social media seem confused why an American thing is so popular in London, it seems as though the American aspect of it is part of the draw. 'It's a subtle flex that you've been to America,' one person commented on a TikTok.
Yahoo
14 hours ago
- Yahoo
New Solana Launchpad, Token Mill, Bets Traders (Mostly) Care Only About Price Pumps
An upcoming token launchpad on Solana plans to drive usership and volumes to its platform by focusing on one thing it says matters most to microcap traders: Token prices going up. Put fair launches, creator fees and community-friendly features in the backseat. Token Mill, which launches on Thursday at 16:00 UTC, comes with a design that doesn't try to be fairer or cheaper. It instead focuses on the volatility of tokens when they are issued, giving traders a reason to use the service and drive fees for the platform in doing so. Token Mill comes from the team behind Avalanche-focused Joe and Mantle-focused Merchant Moe. In 2021, Trader Joe was among the largest decentralized exchange (DEX) by volume and mindshare, but has taken a hit in user base after a general migration of liquidity and users away from Avalanche in favor of Solana and newer ecosystems, such as Base. Solana's the leader of token issuance platforms, has been nearly untouchable since its inception in early 2024. The platform's stripped-down model — instant token creation, immediate liquidity, and a flat 1% fee — generated an estimated $800 million in annual revenue and became the cycle's killer app. Competitors like BagsApp, and HeavenDex tried to win market share with revenue share schemes and buyback promises, but each faded after a brief surge. At the center of Token Mill is a mechanic called King of the Mill. Tokens are divided into three market-cap tiers — Bronze ($50,000–$250,000), Silver ($250,000–$1 million) and Gold ($1 million–$10 million). Every 30 minutes, tokens in each tier battle for the crown, with the winner decided by trading volume in the final minutes of the round. The twist is that platform fees from that round are used to buy and burn the winning token, creating a feedback loop of visibility and price spikes. The pitch is that one big runner can trigger a chain of smaller ones. Each race attracts more traders chasing the crown, each crown generates new fees, and each buy-and-burn sets the stage for the next pump. In theory, the wheel never stops turning. 'The nature of this flywheel also means one big runner is enough to generate a dozen smaller ones, creating an ecosystem where everyone eats,' founder @cryptofishx wrote on X. 'Trickle down economics.' Token Mill also adds its own spin on bonding curves. Rather than forcing a token to migrate midway through its lifecycle, the platform combines two Uniswap v3-style pools into a single curve: one that runs until 80% of the supply is minted, and another that activates afterward to mimic a graduation phase. The aim is to carry tokens from launch to maturity without interruption The question is whether any of this can dent dominance. But Token Mill is betting that if the volatility loop works as intended, it can carve out space in an ecosystem where every trader is hunting the next runner. 'Every 30 minutes, this cycle resets meaning there's always another opportunity for a runner to emerge. The more tokens compete, the more volume flows, the stronger the pumps, and the faster the flywheel spins,' Token Mill's announcement read. But Solana's trenches have seen plenty of experiments come and go. Whether this flywheel spins long enough to matter will be tested the moment the first crowns are claimed. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15 hours ago
- Associated Press
AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States
Jupiter, FL August 20, 2025 --( )-- AcCELLerated Biologics, LLC, a leading distributor of regenerative medicine technologies, today announced an exclusive agreement with IPG Medical Corporation, a wholly owned subsidiary of IPG Photonics Corporation, to distribute the RegenaLase™ Laser System throughout the United States. This new dual-wavelength laser platform is engineered to treat musculoskeletal soft tissue, including meniscus cartilage and inflammation. The RegenaLase system features two advanced laser modalities: 1550 nm erbium fiber laser for minimally invasive cartilage surgery 980 nm diode laser for non-invasive photobiomodulation therapy This dual functionality enables physicians to provide both in-office pain relief and advanced cartilage treatment — all from a single, compact, and versatile device. 'This partnership with IPG Medical marks a major milestone in regenerative medicine,' said Steve Whyte, CEO and Founder of AcCELLerated Biologics. The 'RegenaLase system merges laser innovation with non-invasive phototherapy, giving physicians powerful tools to reduce pain and restore cartilage—without the complications of traditional surgery. At AcCELLerated Biologics, we remain committed to being first to market with cutting-edge solutions that empower our physicians to deliver exceptional care to their patients.' 'I recently attended a cadaver training course at RMTI in Jupiter, Florida, to learn in detail how the RegenaLase Laser can treat musculoskeletal pathologies. This laser technology is poised to be a game changer,' said Joshua G. Hackel, MD, FAAFP, RMSK, CAQSM, Sports Medicine Specialist at the Andrews Institute for Orthopaedics and Sports Medicine. 'We are looking forward to conducting a prospective study utilizing the RegenaLase Laser System to treat knee osteoarthritis at the Andrews Research and Education Foundation in Gulf Breeze, Florida.' 'I have been fortunate in my career to be involved in some groundbreaking technology and techniques. It has allowed me to help many patients heal from their injuries,' said Michael A. Scarpone, D.O. Scarpone Sports Regenerative, Steubenville, Ohio. 'The RegenaLase laser is one of those technologies that has the potential to help a great many patients with knee osteoarthritis and beyond. I am excited to be participating in this project — past, present, and future.' Clinical studies have demonstrated the effectiveness of RegenaLase when paired with optional biologic adjuncts such as Platelet-Rich Plasma (PRP), adipose tissue, and bone marrow aspirate. Patients have shown significant reductions in pain and measurable improvements in joint function. Designed with ergonomics and flexibility in mind, the system is well-suited for both surgical suites and office-based settings, enabling highly personalized treatment protocols, based on delivering multiple, separated microscopic columns of coagulation to the target tissue. 'We're excited to partner with AcCELLerated Biologics to expand access to the RegenaLase system across the United States,' said Alexander Vybornov, IPG Medical Sr. Director of Partnerships & Commercialization. 'With our expertise in laser innovation and AcCELLerated Biologics' strong clinical support and distribution network, more physicians will be empowered to adopt this advanced laser therapy for pain management and advanced musculoskeletal tissue treatment.' The RegenaLase system is FDA-cleared for coagulation of soft tissue including meniscus cartilage, and temporary relief of pain via tissue heating. About AcCELLerated Biologics, LLC AcCELLerated Biologics is a premier distributor of regenerative medicine devices and biologics, dedicated to equipping physicians with the most advanced technologies to improve patient outcomes. Learn More: Media Contact: Sharon Bruneau [email protected] Contact Information: AcCELLerated Biologics Sharon Bruneau +1 (407) 230-3290 Contact via Email Read the full story here: AcCELLerated Biologics to Distribute RegenaLase™ Laser System from IPG Medical Corporation Across the United States Press Release Distributed by
